Recruiting Myalgic Encephalomyelitis Studies in Grand Rapids
Neoadjuvant Darovasertib in Primary Uveal Melanoma
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)...
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs
Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC participant...
Artificial Intelligence to Measure Adherence to Oral Medication
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis....
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2RĪ± Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be adminis...
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)
The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal ...
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ā„ 18 years of age and with suspected recurrent bra...
About Myalgic Encephalomyelitis Clinical Trials in Grand Rapids
Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.
There are currently 7 myalgic encephalomyelitis clinical trials recruiting participants in Grand Rapids, MICHIGAN. These studies are seeking a combined 1,341 participants. Research is being sponsored by IDEAYA Biosciences, Northwell Health, Aulos Bioscience, Inc. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Myalgic Encephalomyelitis Clinical Trials in Grand Rapids ā FAQ
Are there myalgic encephalomyelitis clinical trials in Grand Rapids?
Yes, there are 7 myalgic encephalomyelitis clinical trials currently recruiting in Grand Rapids, MICHIGAN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Grand Rapids?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Grand Rapids research site will contact you about next steps.
Are clinical trials in Grand Rapids free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Grand Rapids studies also compensate for your time and travel.
What myalgic encephalomyelitis treatments are being tested?
The 7 active trials in Grand Rapids are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.
Data updated March 2, 2026 from ClinicalTrials.gov